PRPH ProPhase Labs Inc

Price (delayed)

$6.93

Market cap

$107.49M

P/E Ratio

N/A

Dividend/share

$0.3

EPS

-$0.36

Enterprise value

$113.72M

ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, ...

Highlights
The company's gross margin has surged by 65% YoY
The gross profit has grown by 18% from the previous quarter
The company's quick ratio has shrunk by 52% YoY but it rose by 12% QoQ
The EPS has plunged by 157% from the previous quarter and by 157% YoY
The debt has soared by 50% YoY

Key stats

What are the main financial stats of PRPH
Market
Shares outstanding
15.51M
Market cap
$107.49M
Enterprise value
$113.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.18
Price to sales (P/S)
2.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
Earnings
Revenue
$39.05M
EBIT
-$4.13M
EBITDA
-$1.63M
Free cash flow
-$19.38M
Per share
EPS
-$0.36
Free cash flow per share
-$1.26
Book value per share
$3.18
Revenue per share
$2.53
TBVPS
$3.87
Balance sheet
Total assets
$72.63M
Total liabilities
$24.37M
Debt
$15M
Equity
$48.26M
Working capital
$33.97M
Liquidity
Debt to equity
0.31
Current ratio
4.42
Quick ratio
3.4
Net debt/EBITDA
-3.81
Margins
EBITDA margin
-4.2%
Gross margin
49.3%
Net margin
-13.6%
Operating margin
-16.8%
Efficiency
Return on assets
-8%
Return on equity
-13.3%
Return on invested capital
-8.6%
Return on capital employed
-6.6%
Return on sales
-10.6%
Dividend
Dividend yield
4.33%
DPS
$0.3
Payout ratio
N/A

PRPH stock price

How has the ProPhase Labs stock price performed over time
Intraday
1.61%
1 week
-11.94%
1 month
-4.94%
1 year
-41.91%
YTD
-3.35%
QTD
-3.35%

Financial performance

How have ProPhase Labs's revenue and profit performed over time
Revenue
$39.05M
Gross profit
$19.24M
Operating income
-$6.54M
Net income
-$5.29M
Gross margin
49.3%
Net margin
-13.6%
The net margin has plunged by 162% from the previous quarter and by 5% YoY
The operating income has shrunk by 89% QoQ
The company's gross margin has surged by 65% YoY
The company's operating margin has shrunk by 62% QoQ and by 17% YoY

Growth

What is ProPhase Labs's growth rate over time

Valuation

What is ProPhase Labs stock price valuation
P/E
N/A
P/B
2.18
P/S
2.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
The EPS has plunged by 157% from the previous quarter and by 157% YoY
PRPH's price to book (P/B) is 46% lower than its last 4 quarters average of 4.0 but 3.8% higher than its 5-year quarterly average of 2.1
The P/S is 32% lower than the last 4 quarters average of 4.0 and 24% lower than the 5-year quarterly average of 3.6
PRPH's revenue is up by 17% since the previous quarter

Efficiency

How efficient is ProPhase Labs business performance
ProPhase Labs's return on assets has shrunk by 150% QoQ but it has increased by 26% YoY
PRPH's return on equity has dropped by 133% since the previous quarter but it is up by 10% year-on-year
The return on invested capital is up by 32% year-on-year
The ROS has increased by 16% YoY

Dividends

What is PRPH's dividend history
DPS
$0.3
Dividend yield
4.33%
Payout ratio
N/A
Recent dividends

Financial health

How did ProPhase Labs financials performed over time
PRPH's total assets is 198% greater than its total liabilities
The company's total liabilities has surged by 99% YoY but it fell by 15% QoQ
The company's quick ratio has shrunk by 52% YoY but it rose by 12% QoQ
The debt is 69% less than the equity
PRPH's debt to equity has dropped by 67% year-on-year
The debt has soared by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.